Nancy S. Shulman

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

Edward Gane, Stuart K. Roberts, Catherine AM Stedman et al. · The Lancet · 2010 · 336 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease

Paul J. Pockros, K. Rajender Reddy, Parvez Mantry et al. · Gastroenterology · 2016 · 278 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Ultra‐Deep Pyrosequencing of Hepatitis B Virus Quasispecies from Nucleoside and Nucleotide Reverse‐Transcriptase Inhibitor (NRTI)–Treated Patients and NRTI‐Naive Patients

Severine Margeridon‐Thermet, Nancy S. Shulman, Aijaz Ahmed et al. · The Journal of Infectious Diseases · 2009 · 208 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +17

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection

Nancy Reau, Paul Y. Kwo, Susan Rhee et al. · Hepatology · 2018 · 181 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks

Jordan J. Feld, Christophe Moreno, Roger Trinh et al. · Journal of Hepatology · 2015 · 162 citations · Full text

Medicine, Infectious Diseases, Pharmacotherapy +17